30 April 2020

Health & Safety Notifications

Reference: CIR-2020-00000023

To all health facilities / all health care practitioners in Dubai's private health sector:

Referring to the above subject, DHA notes all health facilities regarding the Circular issued by the MOHAP for information and adhere to what is stated

• Drug Safety communication- Due to possible increased risk of cancer. Belviq XR (lorcaserin)
• Field Safety Notification for medical device Stellar 100, Stellar 150
• Safety alerts for use of unauthorized skin products Clobetasol proprionate 0.05%
• Voluntary Recall of 3 lots of pharmaceutical product Nizatidine Capsules 150mg and 300mg
• warning the use of unauthorized prescription skin products Nadinola Fade Cream _ Neoprosone-Gel Forte
• Warning the use of unauthorized prescription skin products ZO medical

 

Thanks in advance for your good co-operation

Drug Control Section

Health Regulation Sector

DHA

Supporting Documents:

Drug Safety communication- Due to possible increased risk of cancer. Belviq XR (lorcaserin).pdf:

View Document

Field Safety Notification for medical device Stellar 100, Stellar 150.pdf:

View Document

Safety alerts for use of unauthorized skin products Clobetasol proprionate 0.05%.pdf:

View Document

Voluntary Recall of 3 lots of pharmaceutical product Nizatidine Capsules 150mg and 300mg.pdf:

View Document

warning the use of unauthorized prescription skin products Nadinola Fade Cream _ Neoprosone-Gel Forte.pdf:

View Document

Warning the use of unauthorized prescription skin products ZO medical .pdf:

View Document